Immune checkpoint inhibitors (ICIs) have transformed treatment paradigms across many cancers but have shown limited efficacy as monotherapy in well-differentiated pNETs, likely due to low tumor mutational burden and minimal PD-L1 expression [130,131,132]. Here, CD274 is linked to neoplasm.